Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9HCF6

UPID:
TRPM3_HUMAN

ALTERNATIVE NAMES:
Long transient receptor potential channel 3; Melastatin-2

ALTERNATIVE UPACC:
Q9HCF6; A2A3F6; A9Z1Y7; Q5VW02; Q5VW03; Q5VW04; Q5W5T7; Q86SH0; Q86SH6; Q86UL0; Q86WK1; Q86WK2; Q86WK3; Q86WK4; Q86YZ9; Q86Z00; Q86Z01; Q9H0X2

BACKGROUND:
The protein Transient receptor potential cation channel subfamily M member 3, known alternatively as Long transient receptor potential channel 3 or Melastatin-2, is crucial for constitutive calcium ion entry. Its function is enhanced under conditions such as reduced extracellular osmolarity, store depletion, and activation by muscarinic receptors. Additionally, TRPM3 collaborates with TRPM1 to form ion channels permeable to calcium and zinc.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Transient receptor potential cation channel subfamily M member 3 could open doors to potential therapeutic strategies for neurodevelopmental disorders and cataract 50, diseases directly linked to mutations in this protein.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.